![Foto de FLAVIA](/img/uploaded/7CB8017FB3419559B20E8EA8CC3A4F71.jpg)
FLAVIA
FONDEVILA PENA
Forscher/in in der Zeit 2017-2022
Publikationen (11) Publikationen von FLAVIA FONDEVILA PENA
2022
2021
-
Association of foxo3 expression with tumor pathogenesis, prognosis and clinicopathological features in hepatocellular carcinoma: A systematic review with meta-analysis
Cancers, Vol. 13, Núm. 21
-
Autophagy-related chemoprotection against sorafenib in human hepatocarcinoma: Role of foxo3 upregulation and modulation by regorafenib
International Journal of Molecular Sciences, Vol. 22, Núm. 21
-
Melatonin as an antitumor agent against liver cancer: An updated systematic review
Antioxidants, Vol. 10, Núm. 1, pp. 1-27
-
Prognostic and clinicopathological significance of hypoxia-inducible factors 1α and 2α in hepatocellular carcinoma: a systematic review with meta-analysis
Therapeutic Advances in Medical Oncology, Vol. 13
2019
-
Anti-tumoral activity of single and combined regorafenib treatments in preclinical models of liver and gastrointestinal cancers
Experimental and Molecular Medicine, Vol. 51, Núm. 9
-
Antitumor effects of quercetin in hepatocarcinoma in vitro and in vivo models: A systematic review
Nutrients, Vol. 11, Núm. 12
-
Stabilization of hypoxia-inducible factors and BNIP3 promoter methylation contribute to acquired sorafenib resistance in human hepatocarcinoma cells
Cancers, Vol. 11, Núm. 12
2018
-
Sorafenib resistance in hepatocarcinoma: role of hypoxia-inducible factors
Experimental and Molecular Medicine, Vol. 50, Núm. 10
2017
-
Melatonin enhances sorafenib actions in human hepatocarcinoma cells by inhibiting mTORC1/p70S6K/HIF-1α and hypoxiamediated mitophagy
Oncotarget, Vol. 8, Núm. 53, pp. 91402-91414